Apelin

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Friday, March 8, 2024

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
  • This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization

Retrieved on: 
Thursday, October 26, 2023

As part of the collaboration, Lilly will also provide BioAge with tirzepatide.

Key Points: 
  • As part of the collaboration, Lilly will also provide BioAge with tirzepatide.
  • “We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s expertise in obesity drug development,” said Kristen Fortney, PhD, CEO and co-founder of BioAge.
  • “Our Phase 2 trial is designed to assess whether azelaprag can substantially increase the weight loss achieved with drugs of the incretin class.
  • Apelin signaling has demonstrated multiple benefits in energy metabolism in mouse models, including increased insulin sensitivity and reduction in fat mass.

BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest

Retrieved on: 
Monday, December 5, 2022

BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest.

Key Points: 
  • BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest.
  • Twenty-one volunteers underwent 10 days of bed rest while receiving infusions of BGE-105 or placebo.
  • Muscle protein synthesis: Proteomic analysis of muscle microbiopsy samples revealed that bed rest decreased production of muscle proteins, and this effect was significantly ameliorated by BGE-105 (p
  • BioAge has multiple programs targeting muscle, immune, and brain aging, including the clinical-stage apelin receptor agonist BGE-105 and a differentiated CNS-penetrant NLRP3 inhibitor.

APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 30, 2022

Our small molecule candidate, APT-101 has shown the potential to protect the vascular endothelium from damage and also regenerate damaged lung tissue in animal models of pulmonary fibrosis.

Key Points: 
  • Our small molecule candidate, APT-101 has shown the potential to protect the vascular endothelium from damage and also regenerate damaged lung tissue in animal models of pulmonary fibrosis.
  • The apelinergic system plays a key role in the maintenance of vascular health and function through regulation of fibrosis, cell proliferation and inflammation.
  • Further, activation of the apelinergic system through APJ has been shown to regenerate the small capillary blood vessels that are damaged by inflammation and fibrosis, which are characteristic of ILD.
  • In animal models of pulmonary fibrosis, APIE Tx has demonstrated that APT-101 diminishes the onset of fibrosis when administered before its onset and reduces collagen buildup and fibrosis when administered following pulmonary damage.

Hemp, Inc.’s CBDA and CBGA Products on Sale Now

Retrieved on: 
Tuesday, July 19, 2022

The Company announced its CBDA and CBGA capsules are in stock and available for sale.

Key Points: 
  • The Company announced its CBDA and CBGA capsules are in stock and available for sale.
  • Many anticipate OSUs study will generate a huge rush-to-market but Hemp, Inc. is already ahead of the curve, as its CBD line can easily be reformulated with CBDA and CBGA.
  • According to another source , CBGA (cannabigerolic acid) is the "mother cannabinoid" of popular compounds such as CBD and THC.
  • CBGA converts to other precursor compounds, one of which is CBDA (cannabidiolic acid).

BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications

Retrieved on: 
Tuesday, April 19, 2022

Apelin, the natural ligand of the APJ receptor, regulates multiple aspects of muscle metabolism, growth, and repair.

Key Points: 
  • Apelin, the natural ligand of the APJ receptor, regulates multiple aspects of muscle metabolism, growth, and repair.
  • We believe that BGE-105 has the potential to prevent muscle atrophy and improve muscle function in older adults.
  • Following completion of the Phase 1b trial, BioAge will proceed with a Phase 2 proof-of-concept trial of BGE-105 to improve recovery in patients with hospitalization-related muscle atrophy, an acute indication with high unmet medical need.
  • In April 2021, BioAge entered into an exclusive worldwide license agreement with Amgen, Inc. to develop and commercialize BGE-105 to ameliorate muscle aging [ link ].

Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards

Retrieved on: 
Friday, September 10, 2021

Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Key Points: 
  • Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
  • The PHAB Awards in recognizing the dedicated efforts of worthy researchers, underscores Bayers commitment to health for all.
  • Samuel Rayner, M.D., University of Washington Center for Lung Biology, to study proximal pulmonary vascular compliance and inflammation in PAH.
  • Our online press service is just a click away: www.bayer.us/en/newsroom
    BAYER and the Bayer Cross are registered trademarks of Bayer.

BioAge Signs Exclusive Agreement With Amgen To Develop and Commercialize Amgen’s Phase 1 APJ Agonist To Treat Diseases of Aging

Retrieved on: 
Wednesday, April 14, 2021

\xe2\x80\x9cUsing this robust approach, we found that higher levels of apelin signalling in older people are associated with increased lifespan and reduced symptoms of frailty.

Key Points: 
  • \xe2\x80\x9cUsing this robust approach, we found that higher levels of apelin signalling in older people are associated with increased lifespan and reduced symptoms of frailty.
  • Our human-first analysis suggests that the apelin-mimicking drug BGE-105 could recapitulate these positive effects in older patients.\xe2\x80\x9d\nIn mice, deficiency in apelin or APJ accelerates loss of muscle function.
  • By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.
  • For additional information about BioAge, visit the company\xe2\x80\x99s website at www.bioagelabs.com .\n'

APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer

Retrieved on: 
Thursday, March 18, 2021

Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) -- APIE Therapeutics , a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ), announced the appointment of Robert Willette, Ph.D. to the role of chief scientific officer.

Key Points: 
  • Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) -- APIE Therapeutics , a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ), announced the appointment of Robert Willette, Ph.D. to the role of chief scientific officer.
  • His expertise in this space will be crucial as we advance our lead candidates, APT-101 and APT-102 into human clinical trials.
  • Dr. Willette recently served as interim chief science officer at Complexa Therapeutics and ImmunoMet Therapeutics.
  • Products like those in the APIE Therapeutics pipeline that address micro-vascular injury/repair could have significant potential to treat currently intractable diseases.

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

Retrieved on: 
Wednesday, December 9, 2020

The company expects the apelin agonists to have potential to treat COVID-19 associated ARDS as well as ARDS patients in general, of which there are approximately three million globally.

Key Points: 
  • The company expects the apelin agonists to have potential to treat COVID-19 associated ARDS as well as ARDS patients in general, of which there are approximately three million globally.
  • We plan to complete additional ongoing studies and submit the combined data for presentation at a future scientific meeting.
  • The data for CohBars apelin agonists in this preclinical model are encouraging and support further advancement of the program towards candidate selection for clinical testing.
  • Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.